Experts share how careers can move
from the bench to IPO and beyond
from the bench to IPO and beyond
When:
Thursday, September 15, 2011, 4–5pm
Reception to Follow, 5-6p
Where:
Robert Mahley Auditorium
The J. David Gladstone Institutes
1650 Owens St
San Francisco, CA 94158
Panelists:
Douglas Crawford, PhD
Douglas Crawford’s goal is to help stimulate economic growth in California by promoting cross-discipline academic research and accelerating the transfer of the resulting innovations to the market. Crawford created and manages the first incubator within the University of California, the QB3 Garage@UCSF, which has now expanded to include the QB3 Garage@Berkeley, the QB3 Mission Bay Innovation Center, and the QB3 East Bay Innovation Center. Together these incubators are currently home to 42 companies. Crawford is also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage venture fund that seeks to make pivotal early-stage investments in bioscience companies emerging from UC. He is a board member of Redwood Biosciences (observer), Delpor, and the BayBio Institute. Crawford received his PhD in biochemistry from UCSF.
Erik Lium, PhD
Felice Lu, PhD
Felice joined the Office of Technology Managment (OTM) in September 2008 where her responsibilities include technology management, licensing, and outgoing material transfer agreements. Prior to joining the OTM, Felice analyzed investment opportunities in the diagnostic, biopharmaceutical, and medical device industries for the venture capital firms Canaan Partners and Burrill & Company. Previously she worked as a market analyst at Genentech, performing market and product reviews and competitive assessments. During graduate school, Felice interned at the OTM while conducting research in the areas of computational and medicinal chemistry. Felice holds a Ph.D. in chemistry and chemical biology from UCSF and a B.S. in chemistry from Harvey Mudd College.
KT Moortgat, PhD
KT Moortgat brings her experience enabling university entrepreneurs and translating discovery into commercial opportunities to her work as a Partner and member of the investment team at Mohr Davidow. She identifies and engages innovators, entrepreneurs, and thought leaders in support of the firm’s Cleantech and Life Sciences investment areas. She also manages the MDV Innovators Award.
Before joining Mohr Davidow, KT founded and led the Center for BioEntrepreneurship, within UC San Francisco and affiliated with the QB3 Institute. She established the hub of UCSF’s training and resources for entrepreneurial scientists and clinicians, including the popular “Idea to IPO ... and Beyond” course, and “Intellectual Property for Life Scientists”. She also mentored dozens of faculty and students in commercializing life science technologies. At UCSF, she worked closely with the Executive Vice Chancellor on developing a strategy for industry-academic partnerships. KT earned a doctorate in Biophysics for research conducted at the Salk Institute and Scripps Institution of Oceanography, and was awarded a NIH Predoctoral Fellowship to complete this work. She has masters and undergraduate degrees in Physics from UC San Diego and Berkeley, respectively. At UC San Francisco she was Sloan Postdoctoral Fellow.
KT serves on the advisory committee for the Kauffman Foundation’s Postdoctoral Entrepreneur Award.
Michael Schwartz, MS
Michael Schwartz is a biomedical entrepreneur with experience across the drug discovery, diagnostic, and medical device sectors. He was a co-founder of Fluxion Biosciences and currently is director of marketing and business development. At Fluxion, Michael has the led the development and commercialization of numerous microfluidic devices and instruments for drug discovery and diagnostic applications. Previously, Michael held development and marketing roles at Advanced Stent Technologies, a medical device firm focused on coronary stents (acquired:Boston Scientific). He has also held development positions at BioCardia and Converge Medical. Michael received his BS, Bioengineering from UC Berkeley and MS, Bioengineering from Columbia University.
Jim Wells, PhD
Jim Wells is a professor and chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy. He holds a combined appointment as professor in the Department of Cellular & Molecular Pharmacology in the School of Medicine. He joined UCSF in 2005 as holder of the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences. Wells also founded and directs the Small Molecule Discovery Center (SMDC) located at UCSF’s Mission Bay campus. He earned a PhD degree in biochemistry from Washington State University with Professor Ralph Yount in 1979 and completed postdoctoral work at Stanford University School of Medicine with Professor George Stark in 1982. Before joining UCSF, Wells was the founding scientist in Genentech’s Protein Engineering Department and in 1998 co-founded Sunesis Pharmaceuticals.
*This event is co-sponsored by the Gladstone Postdoc Advisory Committee
Thursday, September 15, 2011, 4–5pm
Reception to Follow, 5-6p
Where:
Robert Mahley Auditorium
The J. David Gladstone Institutes
1650 Owens St
San Francisco, CA 94158
Panelists:
Douglas Crawford, PhD
Douglas Crawford’s goal is to help stimulate economic growth in California by promoting cross-discipline academic research and accelerating the transfer of the resulting innovations to the market. Crawford created and manages the first incubator within the University of California, the QB3 Garage@UCSF, which has now expanded to include the QB3 Garage@Berkeley, the QB3 Mission Bay Innovation Center, and the QB3 East Bay Innovation Center. Together these incubators are currently home to 42 companies. Crawford is also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage venture fund that seeks to make pivotal early-stage investments in bioscience companies emerging from UC. He is a board member of Redwood Biosciences (observer), Delpor, and the BayBio Institute. Crawford received his PhD in biochemistry from UCSF.
Erik Lium, PhD
Dr. Lium serves as the Assistant Vice Chancellor of the Office of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF). Prior to this position Lium served as Assistant Vice Chancellor for Research, Director of the Industry Contracts Division and Interim Director of the Contracts & Grants Division of the Office of Sponsored Research, and Director of Business Development for the UCSF Diabetes Center & Immune Tolerance Network. Lium has advanced the research, instruction, and public service mission of UCSF through substantial improvements to institutional research support services, and directly contributed to UCSF being recognized as an institution committed to innovative research alliances. Lium was President of LabVelocity Inc., an information services company focused on accelerating life science R&D processes, prior to its acquisition in 2004. He served as a postdoctoral research scientist in the laboratory of J. Michael Bishop, MD at UCSF, and earned his Ph.D. with honors from the Integrated Program in Cellular, Molecular, and Biophysical Studies at Columbia University in the laboratory of Saul J. Silverstein, Ph.D.
Felice Lu, PhD
Felice joined the Office of Technology Managment (OTM) in September 2008 where her responsibilities include technology management, licensing, and outgoing material transfer agreements. Prior to joining the OTM, Felice analyzed investment opportunities in the diagnostic, biopharmaceutical, and medical device industries for the venture capital firms Canaan Partners and Burrill & Company. Previously she worked as a market analyst at Genentech, performing market and product reviews and competitive assessments. During graduate school, Felice interned at the OTM while conducting research in the areas of computational and medicinal chemistry. Felice holds a Ph.D. in chemistry and chemical biology from UCSF and a B.S. in chemistry from Harvey Mudd College.
KT Moortgat, PhD
KT Moortgat brings her experience enabling university entrepreneurs and translating discovery into commercial opportunities to her work as a Partner and member of the investment team at Mohr Davidow. She identifies and engages innovators, entrepreneurs, and thought leaders in support of the firm’s Cleantech and Life Sciences investment areas. She also manages the MDV Innovators Award.
Before joining Mohr Davidow, KT founded and led the Center for BioEntrepreneurship, within UC San Francisco and affiliated with the QB3 Institute. She established the hub of UCSF’s training and resources for entrepreneurial scientists and clinicians, including the popular “Idea to IPO ... and Beyond” course, and “Intellectual Property for Life Scientists”. She also mentored dozens of faculty and students in commercializing life science technologies. At UCSF, she worked closely with the Executive Vice Chancellor on developing a strategy for industry-academic partnerships. KT earned a doctorate in Biophysics for research conducted at the Salk Institute and Scripps Institution of Oceanography, and was awarded a NIH Predoctoral Fellowship to complete this work. She has masters and undergraduate degrees in Physics from UC San Diego and Berkeley, respectively. At UC San Francisco she was Sloan Postdoctoral Fellow.
KT serves on the advisory committee for the Kauffman Foundation’s Postdoctoral Entrepreneur Award.
Michael Schwartz, MS
Michael Schwartz is a biomedical entrepreneur with experience across the drug discovery, diagnostic, and medical device sectors. He was a co-founder of Fluxion Biosciences and currently is director of marketing and business development. At Fluxion, Michael has the led the development and commercialization of numerous microfluidic devices and instruments for drug discovery and diagnostic applications. Previously, Michael held development and marketing roles at Advanced Stent Technologies, a medical device firm focused on coronary stents (acquired:Boston Scientific). He has also held development positions at BioCardia and Converge Medical. Michael received his BS, Bioengineering from UC Berkeley and MS, Bioengineering from Columbia University.
Jim Wells, PhD
Jim Wells is a professor and chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy. He holds a combined appointment as professor in the Department of Cellular & Molecular Pharmacology in the School of Medicine. He joined UCSF in 2005 as holder of the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences. Wells also founded and directs the Small Molecule Discovery Center (SMDC) located at UCSF’s Mission Bay campus. He earned a PhD degree in biochemistry from Washington State University with Professor Ralph Yount in 1979 and completed postdoctoral work at Stanford University School of Medicine with Professor George Stark in 1982. Before joining UCSF, Wells was the founding scientist in Genentech’s Protein Engineering Department and in 1998 co-founded Sunesis Pharmaceuticals.
*This event is co-sponsored by the Gladstone Postdoc Advisory Committee